Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Efficacy and Safety of Anti-SARS-CoV-2 Inactivated Convalescent Plasma in the Treatment of Novel Coronavirus Pneumonia Patient (COVID-19) : An Observational Study

NCT04292340 is registered in ClinicalTrials.gov with Shanghai Public Health Clinical Center as lead sponsor.

NCT NCT04292340
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04292340 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Efficacy and Safety of Anti-SARS-CoV-2 Inactivated Convalescent Plasma in the Treatment of Novel Coronavirus Pneumonia Patient (COVID-19) : An Observational Study
Lead sponsor
Shanghai Public Health Clinical Center
Phase
Observational
Overall status
Unknown status
Start date
February 1, 2020
Completion date
December 31, 2020
Enrollment
15 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

coronavirus